Cherian K Kandathil1, Sonam Dilwali, Chen-Chi Wu, Metin Ibrahimov, Michael J McKenna, Hang Lee, Konstantina M Stankovic. 1. *Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston; †Department of Otology and Laryngology, Harvard Medical School, Boston; ‡Program in Speech and Hearing Bioscience and Technology, Harvard Medical School and Massachusetts Institute of Technology, Cambridge; and §Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, U.S.A.
Abstract
OBJECTIVE: Given the presence of a pathological immune response in sporadic vestibular schwannoma (sVS), this study aims to explore the roles of aspirin in minimizing sVS growth in vivo. STUDY DESIGN: Retrospective case review. SETTING: Tertiary care hospital. PATIENTS: People diagnosed with sVS and followed at a tertiary referral center by serial magnetic resonance imaging (MRI) for at least 4 months within the period of January 1980 through April 2012. MAIN OUTCOME MEASURES: Patient use of aspirin and sVS growth rate measured by changes in the largest tumor dimension as noted on serial MRIs RESULTS: Within a set of 689 cases, 347 were followed by serial MRI scans (50.3%); of the latter, 81 took aspirin, of which, 33 demonstrated sVS growth, and 48 did not. Of the 266 nonaspirin users, 154 demonstrated sVS growth, and 112 did not. A significant inverse association was found among aspirin users and sVS growth (odds ratio [OR]: 0.50, 95% confidence interval [CI]: 0.29-0.85), which was not confounded by age or sex. CONCLUSION: Our results suggest a potential therapeutic role of aspirin in inhibiting sVS growth.
OBJECTIVE: Given the presence of a pathological immune response in sporadic vestibular schwannoma (sVS), this study aims to explore the roles of aspirin in minimizing sVS growth in vivo. STUDY DESIGN: Retrospective case review. SETTING: Tertiary care hospital. PATIENTS: People diagnosed with sVS and followed at a tertiary referral center by serial magnetic resonance imaging (MRI) for at least 4 months within the period of January 1980 through April 2012. MAIN OUTCOME MEASURES: Patient use of aspirin and sVS growth rate measured by changes in the largest tumor dimension as noted on serial MRIs RESULTS: Within a set of 689 cases, 347 were followed by serial MRI scans (50.3%); of the latter, 81 took aspirin, of which, 33 demonstrated sVS growth, and 48 did not. Of the 266 nonaspirin users, 154 demonstrated sVS growth, and 112 did not. A significant inverse association was found among aspirin users and sVS growth (odds ratio [OR]: 0.50, 95% confidence interval [CI]: 0.29-0.85), which was not confounded by age or sex. CONCLUSION: Our results suggest a potential therapeutic role of aspirin in inhibiting sVS growth.
Authors: Christopher S Graffeo; Avital Perry; Aditya Raghunathan; Trynda N Kroneman; Mark Jentoft; Colin L Driscoll; Brian A Neff; Matthew L Carlson; Jeffrey Jacob; Michael J Link; Jamie J Van Gompel Journal: J Neurol Surg B Skull Base Date: 2018-02-07
Authors: Katrina Hannah D Ignacio; Adrian I Espiritu; Jose Danilo B Diestro; Kevin Ivan Chan; Adam A Dmytriw; Abdelsimar T Omar Journal: Neurol Sci Date: 2021-03-26 Impact factor: 3.307
Authors: Jacob B Hunter; David O Francis; Brendan P O'Connell; Edmond K Kabagambe; Marc L Bennett; George B Wanna; Alejandro Rivas; Reid C Thompson; David S Haynes Journal: Otol Neurotol Date: 2016-12 Impact factor: 2.311
Authors: Alexander D Sherry; Brian Bingham; Ellen Kim; Meredith Monsour; Guozhen Luo; Albert Attia; Lola B Chambless; Anthony J Cmelak Journal: J Radiosurg SBRT Date: 2020
Authors: William Guerrant; Smitha Kota; Scott Troutman; Vinay Mandati; Mohammad Fallahi; Anat Stemmer-Rachamimov; Joseph L Kissil Journal: Cancer Res Date: 2016-05-23 Impact factor: 12.701
Authors: Alexander Schulz; Robert Büttner; Christian Hagel; Stephan L Baader; Lan Kluwe; Johannes Salamon; Victor-Felix Mautner; Thomas Mindos; David B Parkinson; Jeffrey R Gehlhausen; D Wade Clapp; Helen Morrison Journal: Acta Neuropathol Date: 2016-05-28 Impact factor: 17.088
Authors: Benjamin M Wahle; Eric T Hawley; Yongzheng He; Abbi E Smith; Jin Yuan; Andi R Masters; David R Jones; Jeffrey R Gehlhausen; Su-Jung Park; Simon J Conway; D Wade Clapp; Charles W Yates Journal: Oncotarget Date: 2017-10-24